This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hastings, J. C. Articles by Tomassini, J. E. Search for Related Content PubMed PubMed Citation Articles by Hastings, J. C. Articles by Tomassini, J. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 1996, 1304-1307, Vol 40, No. 5
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors

JC Hastings, H Selnick, B Wolanski and JE Tomassini
Department of Antiviral Research, Merck Research Laboratories, West Point, Pennsylvania 19486-0004, USA.

We previously identified a series of compounds which specifically inhibited the transcription of influenza A and B viruses (J. Tomassini, H. Selnick, M.E. Davies, M.E. Armstrong, J. Baldwin, M. Bourgeois, J. Hastings, D. Hazuda, J. Lewis, W. McClements, G. Ponticello, E. Radzilowski, G. Smith, A. Tebben, and A. Wolfe, Antimicrob. Agents Chemother. 38:2827-2837, 1994). The compounds, 4-substituted 2,4- dioxobutanoic acids, selectively targeted the cap-dependent endonuclease activity of the transcriptase complex. Additionally, several of these compounds effectively inhibited the replication of influenza virus but not other viruses in cell culture assays. Here, we report on the anti-influenza virus activities of other potent derivatives of the series evaluated in both in vitro and in vivo infectivity assays. These compounds inhibited the replication of influenza virus in yield reduction assays, with 50% inhibitory concentrations ranging from 0.18 to 0.71 microM. These 50% inhibitory concentrations were similar to those observed for inhibition of in vitro transcription (0.32 to 0.54 microM). One selected compound also elicited a dose-dependent inhibition of influenza virus replication in mice following an upper respiratory tract challenge. These studies demonstrate the antiviral efficacy of this inhibitor class and thereby establish the utility of influenza virus endonuclease as a chemotherapeutic target.

This article has been cited by other articles:

• Zhao, C., Lou, Z., Guo, Y., Ma, M., Chen, Y., Liang, S., Zhang, L., Chen, S., Li, X., Liu, Y., Bartlam, M., Rao, Z. (2009). Nucleoside Monophosphate Complex Structures of the Endonuclease Domain from the Influenza Virus Polymerase PA Subunit Reveal the Substrate Binding Site inside the Catalytic Center. J. Virol. 83: 9024-9030 [Abstract] [Full Text]  
• Klumpp, K., Hang, J. Q., Rajendran, S., Yang, Y., Derosier, A., Wong Kai In, P., Overton, H., Parkes, K. E. B., Cammack, N., Martin, J. A. (2003). Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res 31: 6852-6859 [Abstract] [Full Text]